Faeth Therapeutics (FTH) Net Cash Flow (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Net Cash Flow came in at $143.7 million in Q1 2026, up 122883.76% YoY from N/an in Q1 2025, and up 7684.85% on a QoQ basis from -$1.9 million in Q4 2025.
Faeth Therapeutics (FTH) Net Cash Flow (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Net Cash Flow data on file, last reported at $143.7 million in Q1 2026.
- Quarterly Net Cash Flow rose 122883.76% year-over-year to $143.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $142.4 million (up 13301.85% YoY) and the FY2025 annual result came in at -$1.3 million, up 56.05% from the prior year.
- Net Cash Flow grew to $143.7 million in Q1 2026, from -$1.9 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $143.7 million in Q1 2026 to a low of -$9.7 million in Q1 2023.
- A 5-year average of $8.6 million and a median of $1.3 million in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow tumbled 720.1% — and 2026, when it soared 122883.76%.
- Tracing FTH's Net Cash Flow over 5 years: stood at $6.3 million in 2022, then tumbled by 73.71% to $1.7 million in 2023, then sank by 647.78% to -$9.1 million in 2024, then jumped by 79.27% to -$1.9 million in 2025, then surged by 7684.85% to $143.7 million in 2026.
- The last three Net Cash Flow figures came in at $143.7 million (Q1 2026), -$1.9 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Faeth Therapeutics | 179.31 Mn | 179.31 Mn | - | -125.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -125.42 Mn |
| Jun 30, 2026 | -125.42 Mn |
| Mar 31, 2026 | 143.66 Mn |
| Mar 31, 2026 | 143.66 Mn |
| Dec 31, 2025 | -1.89 Mn |
| Dec 31, 2025 | -1.89 Mn |
| Sep 30, 2025 | -2.00 Mn |
| Sep 30, 2025 | -2.00 Mn |
| Jun 30, 2025 | 2.68 Mn |
| Jun 30, 2025 | 2.68 Mn |
| Mar 31, 2025 | -117,000.00 |
| Mar 31, 2025 | -117,000.00 |
| Dec 31, 2024 | -9.14 Mn |
| Dec 31, 2024 | -9.14 Mn |
| Sep 30, 2024 | 7.24 Mn |
| Sep 30, 2024 | 7.24 Mn |
| Jun 30, 2024 | 935,000.00 |
| Jun 30, 2024 | 935,000.00 |
| Mar 31, 2024 | -2.06 Mn |
| Mar 31, 2024 | -2.06 Mn |